Nano Dimension (TASE:NNDM,NASDAQ:NNDM), a leader in the field of 3D printed electronics, has supplied, in return for payment, its flagship DragonFly 2020 electronics 3D Printer to Syqe Medical Ltd. Syqe is the Tel Aviv-based developer of the world’s first selective-dose, pharmaceutical grade medical cannabis inhaler.

It uses 3D printers to prototype and produce inhalers, which have been used in Israel’s Rambam Hospital for more than a year. Syqe Medical joins the growing ranks of Nano Dimension’s beta clients, and plans to use Nano Dimension’s technology to further develop its inhalers.


 Nano Dimension’s beta program involves the delivery of the company’s DragonFly 2020 3D Printers to leading companies and partners worldwide through a leasing model. These customers are pioneering additive manufacturing technology and techniques for electronics and circuitry, and are active in a variety of industries, including: defense, consumer goods, technology for the finance industry and medical devices.

The customers will qualify the DragonFly 2020 technology and will use it to speed up their product development cycles. The DragonFly 2020 3D printer also allows them to strengthen their in-house innovation capabilities, while providing them with enhanced R&D IP security. In return, companies make payments on their leases and provide Nano Dimension with valuable feedback for further product development.

Nano Dimension, founded in 2012, focuses on development of advanced 3D printed electronics systems and advanced additive manufacturing. Nano Dimension’s unique products combine three advanced technologies: 3D inkjet, 3D software and nanomaterials.

The company’s primary products include the first 3D printer dedicated to printing multi-layer PCBs (printed circuit boards) and advanced nanotechnology-based conductive and dielectric inks. The company’s American Depositary Shares are traded on the NASDAQ, and its ordinary shares are also traded on the TASE in Israel. The Bank of New York Mellon serves as the depositary for Nano Dimension.

Syqe Medical is transforming cannabis and other plants into standard prescription medicines. The first plant the company enabled for use in its inhaler is medical cannabis. Syqe was founded in 2011. In 2013 Prof. Elon Eisenberg conducted the company’s first clinical trial at Rambam Healthcare Campus, in Haifa, which demonstrated the inhaler’s precision and compliance with pharmaceutical standards. In 2016, Syqe announced it had signed an agreement with Teva Pharmaceutical Industries Ltd., the world’s largest manufacturer of generic drugs, to market and distribute Syqe inhalers in Israel.

– FinCanna Capital Corp. (CSE:CALI) (OTCQB:FNNZF), based in Vancouver, BC today announced that Andriyko Herchak, CEO, will present live at VirtualInvestorConferences.com on December 3 rd .

Keep reading... Show less

First-of-its-kind trial in Canada will pave the way for expanded MDMA-assisted treatment to support patients with posttraumatic stress disorder

Keep reading... Show less

Multi-year partnership designates BioSteel as new official sports drink of Philadelphia 76ers team, Training Complex, and the presenting partner of 76ers Training Camp

BioSteel today announced a multi-year deal with the Philadelphia 76ers, making the sports hydration company the official sports drink of the team. BioSteel will also serve as a partner of the Philadelphia 76ers Training Complex, and the presenting partner for 76ers Training Camp, which begins next week.

Keep reading... Show less

Achievements with Scalability and Compatibility Pave Way for Next Phase of Advancement

Codebase Ventures Inc. (“Codebase” or the “Company”) (CSE:CODE)(FSE:C5B)(OTCQB:BKLLF) is excited to announce that the Company’s holding, Arcology, a cluster-computing powered AI blockchain ecosystem with unlimited scalability, has updated its working roadmap in response to its Testnet 1.0 results

Keep reading... Show less

For the purposes of the Financial Conduct Authority’s Disclosure Guidance and Transparency Rules, World High Life announces that the Company has 230,119,819 ordinary shares of 1p each in issue (“Ordinary Shares”), each share carrying the right to one vote. The figure of 230,119,819 should be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority’s Disclosure Guidance and Transparency Rules

The Directors of the Company accept responsibility for the contents of this announcement.

Keep reading... Show less